China

China’s Clover completes $43M series B

December 10, 2019

BEIJING – Chengdu-based Sichuan Clover Biopharmaceuticals Inc. closed a series B financing round to inject another $43 million into its drug development and manufacturing operations, with a focus on biologic candidate SCB-313, developed with its Trimer-Tag technology platform.

Emphasizing synergy and efficiency, EOC Pharma raises $71M series C to fight breast, gastric cancers

December 10, 2019

By Elise Mak

No Comments

BEIJING – EOC Pharmaceutical Group, of Shanghai, completed a series C financing round, bagging $71 million to advance its lead programs EOC-103 and EOC-315 for breast and gastric cancers. The round was led by Hangzhou Tigermed Consulting Co. Ltd. and its affiliated funds, TF Capital and Yingke PE. Hanne Capital and Everest Venture Capital also participated in the round. In 2017, EOC raised $32 million in a series B round. All funding participants are China-based.

China updates reimbursement drug list, further encourages innovation at home

December 3, 2019

By Elise Mak

No Comments

BEIJING – China has updated its national reimbursement drug list (NRDL) to include innovative drugs that it has recently approved, including homegrown cancer drugs and foreign imports. Industry experts said they believe it is a move to drive biotech innovation at home.

Chinatrials 12 Summit

Is China ready for first-in-class? Not quite, but we must go ahead with innovation, experts say

November 19, 2019

By Elise Mak

No Comments

SHANGHAI – As Chinese biotech companies talk more about innovation, one question is whether they are ready to move into first-in-class drugs from me-too and fast follow-up drugs. To biotech executives, the China first approval for Fibrogen Inc.'s roxadustat, a first-in-class small molecule for amenorrhea, is a wake-up call.

Chinatrials 12 Summit

Too many PD-1s? Facing a competitive landscape, Chinese firms seek ways to stand out

November 19, 2019

By Elise Mak

No Comments

SHANGHAI – With abundant venture capital and favorable policies, Chinese biotech companies are actively turning themselves from generic makers into innovation-driven players, but the market is getting crowded by too many companies focusing on the same area and even the same targets, a reality that is leading to a lack of differentiation in biotech innovation.

Chinatrials 12 Summit

Foreign pharma can leverage China’s regulatory pragmatism, patients and lower trial costs

November 19, 2019

By Elise Mak

No Comments

SHANGHAI – Now is the time for foreign pharmaceutical companies to include China in their strategies, as the country's recent regulatory reform, vast patient pool and lower costs represent opportunities to score approvals faster, said experts at the Chinatrials12 Summit.

Chinatrials12 Summit

With the help of trial experts, Chinese biotechs set sail for global market

November 13, 2019

By Elise Mak

No Comments

SHANGHAI – Innovation-driven biotech companies are sprouting up in China and they now aim to gain a bigger global presence through conducting clinical trials not just in their home country but also abroad.

Akeso closes $150M series D to advance first-in-class bispecific antibodies

November 7, 2019

By Elise Mak

No Comments

BEIJING – Antibody developer Akeso Biopharma Inc., from China's Guangdong province, closed a $150 million series D financing round to advance its pipeline, especially the two PD-1-based bispecific antibodies, AK-104 and AK-112, aimed to help it stand out in the fierce PD-1 space in China. "A significant portion of the proceeds will go to AK-104 and AK-112, which are both first-in-class drug candidates," Akeso CEO Michelle Xia told BioWorld. This year is a big one for Akeso, as AK-104 and AK-112 received IND approvals from the FDA in March and July, respectively.

China grants conditional approval to Green Valley's GV-971 for Alzheimer's disease

November 6, 2019

By Elise Mak

No Comments

BEIJING – Chinese drug regulators granted conditional approval to Shanghai Green Valley (Group) Co. Ltd.'s marine-derived oligosaccharide, GV-971, to treat Alzheimer's disease (AD), but required further trials to prove the drug's efficacy after marketing.

China investors still wary of CFIUS, but experts see light on the far horizon

October 30, 2019

By Michael Fitzhugh

No Comments

SAN FRANCISCO – At what BIO CEO and President Jim Greenwood called a "Dickensian moment in the history of biotechnology – arguably the best of times and the worst of times" for U.S. industry players, new rules piloted by the Committee on Foreign Investment in the U.S. (CFIUS) have made things even more challenging.

China, BioWorld Asia
RSS

China’s Clover completes $43M series B

Emphasizing synergy and efficiency, EOC Pharma raises $71M series C to fight breast, gastric cancers

China updates reimbursement drug list, further encourages innovation at home

Is China ready for first-in-class? Not quite, but we must go ahead with innovation, experts say

Too many PD-1s? Facing a competitive landscape, Chinese firms seek ways to stand out

Foreign pharma can leverage China’s regulatory pragmatism, patients and lower trial costs

With the help of trial experts, Chinese biotechs set sail for global market

Akeso closes $150M series D to advance first-in-class bispecific antibodies

China grants conditional approval to Green Valley's GV-971 for Alzheimer's disease

China investors still wary of CFIUS, but experts see light on the far horizon

Popular Stories

Bioworld MedTech’s Oncology Extra

FDA gives thumbs up to Cochlear’s implantable bone conduction hearing system

Analysis by U.K. startup Medbelle highlights extent of drug pricing disparity

Buoyed by optimism and love of family, former FDA chief Frank Young leaned into storms

Biopharma companies continue their strong momentum in November

BioWorld Premium

China, BioWorld Asia RSS

Popular Stories

BioWorld Premium

China, BioWorld Asia
RSS